Command Palette

Search for a command to run...

Tier IIIACh-esterase inhibitor142 trials

Galantamine — The Dual-Action Cholinergic Modulator

Galantamine is a naturally occurring alkaloid and dual-action cholinergic agent primarily used to treat cognitive decline in Alzheimer's disease. While its longevity relevance is currently theoretical, its neuroprotective properties and ability to modulate cholinergic signaling make it a molecule of interest for preserving cognitive healthspan.

Mechanism of Action

Galantamine exhibits a unique dual mechanism of action in the central nervous system. It functions as a reversible, competitive inhibitor of acetylcholinesterase (AChE), thereby preventing the breakdown of acetylcholine and increasing cholinergic tone in the synaptic cleft. Additionally, it acts as a positive allosteric modulator of nicotinic acetylcholine receptors (nAChRs), enhancing their sensitivity to acetylcholine. This dual action not only improves cognitive function but also exerts neuroprotective effects, potentially by modulating neuroinflammation and reducing oxidative stress.

Human Trial Evidence

Galantamine is extensively studied in humans for Alzheimer's disease and mild cognitive impairment. Long-term randomized controlled trials demonstrate that it significantly attenuates cognitive decline and improves daily functioning in patients with mild-to-moderate Alzheimer's disease. However, there are no published human trials evaluating its efficacy specifically for longevity or healthspan extension in healthy individuals.

Dosing Protocol

8–24 mg/day is the standard clinical range for cognitive decline, typically starting at 8 mg/day and titrating up to minimize gastrointestinal side effects. Extended-release formulations are taken once daily in the morning with food. Prescription required in most jurisdictions.

Safety & Contraindications

Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, particularly during dose escalation. It is contraindicated in patients with severe hepatic or renal impairment. Caution is advised in individuals with a history of peptic ulcer disease, asthma, or cardiac conduction abnormalities due to its vagotonic effects. Prescription required.

Quick Stats
Evidence TierTier III
Clinical Trials142
Typical Dose8 mg ×2
Est. Cost/Day$0.34
Purity99.5%
Synergistic Compounds
MemantineDonepezilAlpha-GPC
Medical disclaimer: This page is for informational purposes only. Consult a qualified healthcare provider before starting any supplement regimen. Vitaei does not provide medical advice.